{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:27:23Z","timestamp":1778642843651,"version":"3.51.4"},"reference-count":139,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Over the last century, a great deal of effort and resources have been poured into the development of vaccines to protect against malaria, particularly targeting the most widely spread and deadly species of the human-infecting parasites: Plasmodium falciparum. Many of the known proteins the parasite uses to invade human cells have been tested as vaccine candidates. However, precisely because of the importance and immune visibility of these proteins, they tend to be very diverse, and in many cases redundant, which limits their efficacy in vaccine development. With the advent of genomics and constantly improving sequencing technologies, an increasingly clear picture is emerging of the vast genomic diversity of parasites from different geographic areas. This diversity is distributed throughout the genome and includes most of the vaccine candidates tested so far, playing an important role in the low efficacy achieved. Genomics is a powerful tool to search for genes that comply with the most desirable attributes of vaccine targets, allowing us to evaluate function, immunogenicity and also diversity in the worldwide parasite populations. Even predicting how this diversity might evolve and spread in the future becomes possible, and can inform novel vaccine efforts.<\/jats:p>","DOI":"10.3390\/microorganisms8111748","type":"journal-article","created":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T19:03:37Z","timestamp":1604862217000},"page":"1748","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Diversify and Conquer: The Vaccine Escapism of Plasmodium falciparum"],"prefix":"10.3390","volume":"8","author":[{"given":"Alena","family":"Pance","sequence":"first","affiliation":[{"name":"The Wellcome Sanger Institute, Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,7]]},"reference":[{"key":"ref_1","unstructured":"World Health Organisation (2020, October 01). World Malaria Report 2018. Available online: https:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2018\/en\/."},{"key":"ref_2","unstructured":"World Health Organisation (2017). Tables of Malaria Vaccine Projects Globally, World Health Organisation."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature01097","article-title":"Genome sequence of the human malaria parasite Plasmodium falciparum","volume":"419","author":"Gardner","year":"2002","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nature11174","article-title":"Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing","volume":"487","author":"Manske","year":"2012","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1473-3099(19)30392-5","article-title":"Evolution and expansion of multidrug-resistant malaria in southeast Asia: A genomic epidemiology study","volume":"19","author":"Hamilton","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Campino, S., Auburn, S., Kivinen, K., Zongo, I., Ouedraogo, J.B., Mangano, V., Djimde, A., Doumbo, O.K., Kiara, S.M., and Nzila, A. (2011). Population genetic analysis of Plasmodium falciparum parasites using a customized Illumina GoldenGate genotyping assay. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020251"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1038\/s41598-020-60676-1","article-title":"Spatio-temporal dynamics of Plasmodium falciparum transmission within a spatial unit on the Colombian Pacific Coast","volume":"10","author":"Knudson","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1126\/science.aav5427","article-title":"Major subpopulations of Plasmodium falciparum in sub-Saharan Africa","volume":"365","author":"Kamau","year":"2019","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1128\/IAI.00590-06","article-title":"A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge","volume":"74","author":"Dunachie","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"286re285","DOI":"10.1126\/scitranslmed.aaa2373","article-title":"Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults","volume":"7","author":"Ogwang","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Moorthy, V.S., Imoukhuede, E.B., Milligan, P., Bojang, K., Keating, S., Kaye, P., Pinder, M., Gilbert, S.C., Walraven, G., and Greenwood, B.M. (2004). A randomised, double-blind, controlled vaccine efficacy trial of DNA\/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med., 1.","DOI":"10.1371\/journal.pmed.0010033"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tiono, A.B., Nebie, I., Anagnostou, N., Coulibaly, A.S., Bowyer, G., Lam, E., Bougouma, E.C., Ouedraogo, A., Yaro, J.B.B., and Barry, A. (2018). First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5\u201317 months old infants and children. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0208328"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Rts","year":"2015","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Rts","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Rts","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rts, S.C.T.P. (2014). Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: A phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001685"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1473-3099(19)30300-7","article-title":"Long-term incidence of severe malaria following RTS,S\/AS01 vaccination in children and infants in Africa: An open-label 3-year extension study of a phase 3 randomised controlled trial","volume":"19","author":"Tinto","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional Third and Fourth Dose of RTS,S\/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study","volume":"214","author":"Regules","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Moon, J.E., Ockenhouse, C., Regules, J.A., Vekemans, J., Lee, C., Chuang, I., Traskine, M., Jongert, E., Ivinson, K., and Morelle, D. (2020). A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S\/AS01E and RTS,S\/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults. J. Infect. Dis.","DOI":"10.1093\/infdis\/jiaa421"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiw244","article-title":"Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S\/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP","volume":"214","author":"Rampling","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1126\/science.1241800","article-title":"Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine","volume":"341","author":"Seder","year":"2013","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa0805832","article-title":"Protection against a malaria challenge by sporozoite inoculation","volume":"361","author":"Roestenberg","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jongo, S.A., Church, L.W.P., Mtoro, A.T., Chakravarty, S., Ruben, A.J., Swanson Ii, P.A., Kassim, K.R., Mpina, M., Tumbo, A.M., and Milando, F.A. (2019). Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciz1152"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: A randomised, double-blind phase 1 trial","volume":"17","author":"Sissoko","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","article-title":"Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults","volume":"99","author":"Jongo","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against Plasmodium falciparum malaria by PfSPZ Vaccine","volume":"2","author":"Epstein","year":"2017","journal-title":"JCI Insight"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature21060","article-title":"Sterile protection against human malaria by chemoattenuated PfSPZ vaccine","volume":"542","author":"Mordmuller","year":"2017","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Walk, J., Reuling, I.J., Behet, M.C., Meerstein-Kessel, L., Graumans, W., van Gemert, G.J., Siebelink-Stoter, R., van de Vegte-Bolmer, M., Janssen, T., and Teelen, K. (2017). Modest heterologous protection after Plasmodium falciparum sporozoite immunization: A double-blind randomized controlled clinical trial. BMC Med., 15.","DOI":"10.1186\/s12916-017-0923-4"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","article-title":"A field trial to assess a blood-stage malaria vaccine","volume":"365","author":"Thera","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Laurens, M.B., Thera, M.A., Coulibaly, D., Ouattara, A., Kone, A.K., Guindo, A.B., Traore, K., Traore, I., Kouriba, B., and Diallo, D.A. (2013). Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079323"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/infdis\/jiw039","article-title":"Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1\/AS01","volume":"213","author":"Payne","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Spring, M.D., Cummings, J.F., Ockenhouse, C.F., Dutta, S., Reidler, R., Angov, E., Bergmann-Leitner, E., Stewart, V.A., Bittner, S., and Juompan, L. (2009). Phase 1\/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005254"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1016\/j.vaccine.2016.07.041","article-title":"A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children","volume":"34","author":"Sirima","year":"2016","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/cid\/ciy1087","article-title":"Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2","volume":"69","author":"Lalremruata","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Palacpac, N.M., Ntege, E., Yeka, A., Balikagala, B., Suzuki, N., Shirai, H., Yagi, M., Ito, K., Fukushima, W., and Hirota, Y. (2013). Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064073"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.4161\/hv.24941","article-title":"Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection","volume":"9","author":"Tamminga","year":"2013","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e55571","DOI":"10.1371\/journal.pone.0055571","article-title":"DNA prime\/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity","volume":"8","author":"Chuang","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1016\/j.celrep.2017.03.017","article-title":"Cell Traversal Activity Is Important for Plasmodium falciparum Liver Infection in Humanized Mice","volume":"18","author":"Yang","year":"2017","journal-title":"Cell Rep."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Jimah, J.R., Salinas, N.D., Sala-Rabanal, M., Jones, N.G., Sibley, L.D., Nichols, C.G., Schlesinger, P.H., and Tolia, N.H. (2016). Malaria parasite CelTOS targets the inner leaflet of cell membranes for pore-dependent disruption. Elife, 5.","DOI":"10.7554\/eLife.20621"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.parint.2007.04.002","article-title":"A long and winding road: The Plasmodium sporozoite\u2019s journey in the mammalian host","volume":"56","author":"Sinnis","year":"2007","journal-title":"Parasitol. Int."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kumar, H., and Tolia, N.H. (2019). Getting in: The structural biology of malaria invasion. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007943"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.20101488","article-title":"The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host","volume":"208","author":"Coppi","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1073\/pnas.1719660115","article-title":"Alpha-v-containing integrins are host receptors for the Plasmodium falciparum sporozoite surface protein, TRAP","volume":"115","author":"Dundas","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1053\/jhep.2001.24237","article-title":"Malaria sporozoites actively enter and pass through rat Kupffer cells prior to hepatocyte invasion","volume":"33","author":"Pradel","year":"2001","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ishino, T., Yano, K., Chinzei, Y., and Yuda, M. (2004). Cell-passage activity is required for the malarial parasite to cross the liver sinusoidal cell layer. PLoS Biol., 2.","DOI":"10.1371\/journal.pbio.0020004"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1550-7408.1983.tb02931.x","article-title":"Ultrastructural observations on the infection of rat liver by Plasmodium berghei sporozoites in vivo","volume":"30","author":"Meis","year":"1983","journal-title":"J. Protozool."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0972-9062.234631","article-title":"Insights into the early liver stage biology of Plasmodium","volume":"55","author":"Kori","year":"2018","journal-title":"J. Vector Borne Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1586\/erv.12.92","article-title":"Pre-erythrocytic malaria vaccines: Identifying the targets","volume":"11","author":"Duffy","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/emmm.201201677","article-title":"Skin-draining lymph node priming is sufficient to induce sterile immunity against pre-erythrocytic malaria","volume":"5","author":"Obeid","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Radtke, A.J., Kastenmuller, W., Espinosa, D.A., Gerner, M.Y., Tse, S.W., Sinnis, P., Germain, R.N., Zavala, F.P., and Cockburn, I.A. (2015). Lymph-node resident CD8alpha+ dendritic cells capture antigens from migratory malaria sporozoites and induce CD8+ T cell responses. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004637"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00281-012-0345-5","article-title":"The skin: Where malaria infection and the host immune response begin","volume":"34","author":"Sinnis","year":"2012","journal-title":"Semin. Immunopathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fimmu.2020.00190","article-title":"Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens","volume":"11","author":"Bettencourt","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Todryk, S.M., Bejon, P., Mwangi, T., Plebanski, M., Urban, B., Marsh, K., Hill, A.V., and Flanagan, K.L. (2008). Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002027"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"M111.007948","DOI":"10.1074\/mcp.M111.007948","article-title":"Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens","volume":"10","author":"Trieu","year":"2011","journal-title":"Mol. Cell Proteom."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Ken Tucker, A.R.N., Kotraiah, V., Phares, T.W., Tsuji, M., Nardin, E.H., and Gutierrez, G.M. (2016). Pre-Erythrocytic Vaccine Candidates in Malaria. Current Topics in Imalaria, IntechOpen.","DOI":"10.5772\/65592"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara","volume":"102","author":"Webster","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2006.03.029","article-title":"Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area","volume":"24","author":"Bejon","year":"2006","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0005-2736(79)90392-4","article-title":"A study of the incorporation of cytochrome oxidase into planar synthetic membranes","volume":"555","author":"Tredgold","year":"1979","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"104197","DOI":"10.1016\/j.meegid.2020.104197","article-title":"Population genetic structure analysis of thrombospondin-related adhesive protein (TRAP) as a vaccine candidate antigen in worldwide Plasmodium falciparum isolates","volume":"80","author":"Mehrizi","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0166-6851(95)00069-D","article-title":"Sequence variations in the non-repetitive regions of the liver stage-specific antigen-1 (LSA-1) of Plasmodium falciparum from field isolates","volume":"71","author":"Yang","year":"1995","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1365-3024.2000.00324.x","article-title":"Research note: HLA degenerate T-cell epitopes from Plasmodium falciparum liver stage-specific antigen 1 (LSA-1) are highly conserved in isolates from geographically distinct areas","volume":"22","author":"Ravichandran","year":"2000","journal-title":"Parasite Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.gene.2007.12.006","article-title":"Positive selection on the Plasmodium falciparum sporozoite threonine-asparagine-rich protein: Analysis of isolates mainly from low endemic areas","volume":"410","author":"Jongwutiwes","year":"2008","journal-title":"Gene"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/infdis\/jit812","article-title":"PlasmoView: A web-based resource to visualise global Plasmodium falciparum genomic variation","volume":"209","author":"Preston","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41564-018-0254-z","article-title":"Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin","volume":"3","author":"Aliprandini","year":"2018","journal-title":"Nat. Microbiol."},{"key":"ref_68","first-page":"33","article-title":"Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites","volume":"68","author":"Herrington","year":"1990","journal-title":"Bull. World Health Organ."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.vaccine.2004.08.020","article-title":"Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720","volume":"23","author":"Walther","year":"2005","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Audran, R., Lurati-Ruiz, F., Genton, B., Blythman, H.E., Ofori-Anyinam, O., Reymond, C., Corradin, G., and Spertini, F. (2009). The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: A randomized controlled phase I trial. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007304"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic Diversity and Protective Efficacy of the RTS,S\/AS01 Malaria Vaccine","volume":"373","author":"Neafsey","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1038\/s41598-018-24585-8","article-title":"RTS,S\/AS01 malaria vaccine mismatch observed among Plasmodium falciparum isolates from southern and central Africa and globally","volume":"8","author":"Pringle","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12936-018-2513-0","article-title":"Genetic polymorphism and natural selection of circumsporozoite surface protein in Plasmodium falciparum field isolates from Myanmar","volume":"17","author":"Le","year":"2018","journal-title":"Malar. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41579-018-0148-3","article-title":"How elusive can a malaria vaccine be?","volume":"17","author":"Pance","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.vaccine.2017.01.001","article-title":"Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda","volume":"35","author":"Kanoi","year":"2017","journal-title":"Vaccine"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Bergmann-Leitner, E.S., Mease, R.M., De La Vega, P., Savranskaya, T., Polhemus, M., Ockenhouse, C., and Angov, E. (2010). Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012294"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2011.06.053","article-title":"Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS","volume":"29","author":"Legler","year":"2011","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Espinosa, D.A., Vega-Rodriguez, J., Flores-Garcia, Y., Noe, A.R., Munoz, C., Coleman, R., Bruck, T., Haney, K., Stevens, A., and Retallack, D. (2017). The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines. Infect. Immun., 85.","DOI":"10.1128\/IAI.00498-16"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.meegid.2018.01.023","article-title":"Analysis of genetic diversity and population structure of gene encoding cell-traversal protein for ookinetes and sporozoites (CelTOS) vaccine candidate antigen in global Plasmodium falciparum populations","volume":"59","author":"Pirahmadi","year":"2018","journal-title":"Infect. Genet. Evol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.102.2643.202","article-title":"Immunization of Rhesus Monkeys against Malarial Infection (P. Knowlesi) with Killed Parasites and Adjuvants","volume":"102","author":"Freund","year":"1945","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4049\/jimmunol.52.4.325","article-title":"Studies in human malaria; the preparation of vaccines and suspensions containing plasmodia","volume":"52","author":"Heidelberger","year":"1946","journal-title":"J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/216160a0","article-title":"Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei","volume":"216","author":"Nussenzweig","year":"1967","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/hv.6.1.9654","article-title":"Genetically engineered, attenuated whole-cell vaccine approaches for malaria","volume":"6","author":"Vaughan","year":"2010","journal-title":"Hum. Vaccin."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.vaccine.2013.08.007","article-title":"First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers","volume":"31","author":"Spring","year":"2013","journal-title":"Vaccine"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Kublin, J.G., Mikolajczak, S.A., Sack, B.K., Fishbaugher, M.E., Seilie, A., Shelton, L., VonGoedert, T., Firat, M., Magee, S., and Fritzen, E. (2017). Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aad9099"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13073-019-0708-9","article-title":"Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential","volume":"12","author":"Moser","year":"2020","journal-title":"Genome Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1083\/jcb.201206112","article-title":"The cellular and molecular basis for malaria parasite invasion of the human red blood cell","volume":"198","author":"Cowman","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/978-0-387-78267-6_3","article-title":"Erythrocyte invasion by Plasmodium falciparum: Multiple ligand-receptor interactions and phenotypic switching","volume":"47","author":"Duraisingh","year":"2008","journal-title":"Subcell. Biochem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"25655","DOI":"10.1074\/jbc.M114.586495","article-title":"The merozoite surface protein 1 complex is a platform for binding to human erythrocytes by Plasmodium falciparum","volume":"289","author":"Lin","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/femsre\/fuw001","article-title":"Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria","volume":"40","author":"Beeson","year":"2016","journal-title":"Fems Microbiol. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Weiss, G.E., Gilson, P.R., Taechalertpaisarn, T., Tham, W.H., de Jong, N.W., Harvey, K.L., Fowkes, F.J., Barlow, P.N., Rayner, J.C., and Wright, G.J. (2015). Revealing the sequence and resulting cellular morphology of receptor-ligand interactions during Plasmodium falciparum invasion of erythrocytes. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004670"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3389\/fmicb.2019.02712","article-title":"Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines","volume":"10","author":"Salamanca","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.vaccine.2004.05.031","article-title":"Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria","volume":"23","author":"Polley","year":"2004","journal-title":"Vaccine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2ra5","DOI":"10.1126\/scitranslmed.3000257","article-title":"Extreme polymorphism in a vaccine antigen and risk of clinical malaria: Implications for vaccine development","volume":"1","author":"Takala","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12936-017-2137-9","article-title":"A deep sequencing approach to estimate Plasmodium falciparum complexity of infection (COI) and explore apical membrane antigen 1 diversity","volume":"16","author":"Miller","year":"2017","journal-title":"Malar. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3347\/kjp.2018.56.2.153","article-title":"Unraveling Haplotype Diversity of the Apical Membrane Antigen-1 Gene in Plasmodium falciparum Populations in Thailand","volume":"56","author":"Lumkul","year":"2018","journal-title":"Korean J. Parasitol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1128\/IAI.00170-08","article-title":"A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits","volume":"76","author":"Remarque","year":"2008","journal-title":"Infect. Immun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1016\/j.vaccine.2017.09.027","article-title":"Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel(R) in European and African adults: A phase 1a\/1b, randomized, double-blind multi-centre trial","volume":"35","author":"Sirima","year":"2017","journal-title":"Vaccine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fimmu.2017.00743","article-title":"Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy","volume":"8","author":"Spiegel","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Srinivasan, P., Baldeviano, G.C., Miura, K., Diouf, A., Ventocilla, J.A., Leiva, K.P., Lugo-Roman, L., Lucas, C., Orr-Gonzalez, S., and Zhu, D. (2017). A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. npj Vaccines, 2.","DOI":"10.1038\/s41541-017-0015-7"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1086\/423208","article-title":"Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design","volume":"190","author":"Singh","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0166-6851(97)00130-8","article-title":"Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3)","volume":"90","author":"McColl","year":"1997","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-3024.2009.01130.x","article-title":"Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso","volume":"31","author":"Nebie","year":"2009","journal-title":"Parasite Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/IAI.73.12.8017-8026.2005","article-title":"Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen","volume":"73","author":"Audran","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/j.vaccine.2006.05.090","article-title":"Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa","volume":"25","author":"Sirima","year":"2007","journal-title":"Vaccine"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1475-2875-8-163","article-title":"Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months","volume":"8","author":"Lusingu","year":"2009","journal-title":"Malar. J."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Sirima, S.B., Tiono, A.B., Ouedraogo, A., Diarra, A., Ouedraogo, A.L., Yaro, J.B., Ouedraogo, E., Gansane, A., Bougouma, E.C., and Konate, A.T. (2009). Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS ONE, 4.","DOI":"10.1371\/annotation\/3221b8d9-038d-4e67-82fa-de6b1233b459"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1086\/509806","article-title":"Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection","volume":"195","author":"Polley","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12936-016-1566-1","article-title":"Genetic diversity of the merozoite surface protein-3 gene in Plasmodium falciparum populations in Thailand","volume":"15","author":"Pattaradilokrat","year":"2016","journal-title":"Malar. J."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1128\/IAI.68.5.2617-2620.2000","article-title":"Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal","volume":"68","author":"Oeuvray","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/cid\/ciy514","article-title":"The Candidate Blood-stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase 1 Trial in Exposed and Nonexposed Volunteers","volume":"68","author":"Kamaka","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/IAI.00652-09","article-title":"Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c","volume":"77","author":"Olugbile","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4269\/ajtmh.2006.74.191","article-title":"High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children","volume":"74","author":"Okech","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.parint.2010.05.002","article-title":"Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36","volume":"59","author":"Horii","year":"2010","journal-title":"Parasitol. Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.vaccine.2011.12.124","article-title":"Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5","volume":"30","author":"Tanabe","year":"2012","journal-title":"Vaccine"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nature10606","article-title":"Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum","volume":"480","author":"Crosnier","year":"2011","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.vaccine.2012.10.106","article-title":"A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants","volume":"31","author":"Bustamante","year":"2013","journal-title":"Vaccine"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ncomms1615","article-title":"The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody","volume":"2","author":"Douglas","year":"2011","journal-title":"Nat. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Payne, R.O., Silk, S.E., Elias, S.C., Miura, K., Diouf, A., Galaway, F., de Graaf, H., Brendish, N.J., Poulton, I.D., and Griffiths, O.J. (2017). Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight, 2.","DOI":"10.1172\/jci.insight.96381"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijpara.2016.05.002","article-title":"Persistence and immunogenicity of chemically attenuated blood stage Plasmodium falciparum in Aotus monkeys","volume":"46","author":"De","year":"2016","journal-title":"Int J. Parasitol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Stanisic, D.I., Fink, J., Mayer, J., Coghill, S., Gore, L., Liu, X.Q., El-Deeb, I., Rodriguez, I.B., Powell, J., and Willemsen, N.M. (2018). Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naive volunteers: A pilot study. BMC Med., 16.","DOI":"10.1186\/s12916-018-1173-9"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Campino, S., Marin-Menendez, A., Kemp, A., Cross, N., Drought, L., Otto, T.D., Benavente, E.D., Ravenhall, M., Schwach, F., and Girling, G. (2018). A forward genetic screen reveals a primary role for Plasmodium falciparum Reticulocyte Binding Protein Homologue 2a and 2b in determining alternative erythrocyte invasion pathways. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007436"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(18)30324-6","article-title":"Malaria","volume":"391","author":"Ashley","year":"2018","journal-title":"Lancet"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Acquah, F.K., Adjah, J., Williamson, K.C., and Amoah, L.E. (2019). Transmission-Blocking Vaccines: Old Friends and New Prospects. Infect. Immun., 87.","DOI":"10.1128\/IAI.00775-18"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"11193","DOI":"10.1038\/srep11193","article-title":"Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum","volume":"5","author":"Kapulu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1128\/IAI.00016-13","article-title":"Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds","volume":"81","author":"Da","year":"2013","journal-title":"Infect. Immun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4269\/ajtmh.15-0571","article-title":"Pooled Amplicon Deep Sequencing of Candidate Plasmodium falciparum Transmission-Blocking Vaccine Antigens","volume":"94","author":"Juliano","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/332158a0","article-title":"A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria","volume":"332","author":"Patarroyo","year":"1988","journal-title":"Nature"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0140-6736(93)90483-W","article-title":"Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia","volume":"341","author":"Valero","year":"1993","journal-title":"Lancet"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/infdis\/170.2.396","article-title":"A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela","volume":"170","author":"Noya","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(94)90098-1","article-title":"Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador","volume":"12","author":"Sempertegui","year":"1994","journal-title":"Vaccine"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4269\/ajtmh.1998.58.378","article-title":"Evaluation of SPf66 malaria vaccine efficacy in Brazil","volume":"58","author":"Urdaneta","year":"1998","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(94)90505-3","article-title":"Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania","volume":"344","author":"Alonso","year":"1994","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0140-6736(95)91321-1","article-title":"Efficacy trial of malaria vaccine SPf66 in Gambian infants","volume":"346","author":"Leach","year":"1995","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0140-6736(96)04465-0","article-title":"Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group","volume":"348","author":"Nosten","year":"1996","journal-title":"Lancet"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1128\/iai.64.9.3833-3844.1996","article-title":"NYVAC-Pf7: A poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria","volume":"64","author":"Tine","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1086\/515331","article-title":"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria","volume":"177","author":"Ockenhouse","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12936-016-1328-0","article-title":"Analysis of the dose-dependent stage-specific in vitro efficacy of a multi-stage malaria vaccine candidate cocktail","volume":"15","author":"Boes","year":"2016","journal-title":"Malar. J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1016\/j.vaccine.2015.09.110","article-title":"Designing malaria vaccines to circumvent antigen variability","volume":"33","author":"Ouattara","year":"2015","journal-title":"Vaccine"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/8\/11\/1748\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:30:30Z","timestamp":1760178630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/8\/11\/1748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,7]]},"references-count":139,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["microorganisms8111748"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms8111748","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,7]]}}}